Lv41
650 积分 2023-11-14 加入
Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial
1小时前
待确认
An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study
1个月前
已完结
Long‐term efficacy and safety of stapokibart for moderate‐to‐severe atopic dermatitis: 52‐week results from a phase 3 trial
1个月前
已完结
Long-Term Stapokibart Treatment Induces Sustained Clinical Improvements in Patients With Moderate-to-Severe Atopic Dermatitis
1个月前
已关闭
Optimization of a novel 2+2 BCMA x CD3 bispecific antibody for minimized cytokine release and potent efficacy
1个月前
已完结
Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue, in participants with phenotypic metabolic dysfunction-associated steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial
1个月前
已完结
Simultaneous inhibition of fibroblast growth factor-2 and vascular endothelial growth factor-a with RC28-E in diabetic macular edema: a phase 2 randomised trial
2个月前
已完结
Pharmacokinetics analysis based on target-mediated drug distribution for RC18, a novel BLyS/APRIL fusion protein to treat systemic lupus erythematosus and rheumatoid arthritis
2个月前
已完结
Achievable but elusive: LLDAS and DORIS remission in clinical trials of belimumab
2个月前
已完结
Physician’s global assessment is often useful in SLE, but not always: the case of clinical remission
2个月前
已完结
皖公网安备34019202002308
